Increased interest in predictive biomarkers and genomic profiling: There is significant interest in selecting patients who will most likely benefit from certain therapies. Top biomarkers associated with trials to be presented at ESMO 2023 include HER2, EGFR, PD-L1, ALK, BRAF, HR, ROS1, BRCA, MSI-H, and PD-1. Notably, ctDNA and other liquid biopsy approaches are being evaluated as well.

Novel radiopharmaceuticals and radionuclide therapies: Several agents are being actively evaluated in various tumor types, such as prostate, breast, head and neck, and neuroendocrine tumors. The radioligand sector’s momentum continues, with the recent acquisition of Point Biopharma by Eli Lilly. Anticipation is building for significant developments, especially in the context of key prostate cancer trials

Neoadjuvant and adjuvant therapies continue to be important: Evaluating therapies earlier in the disease course is an area of focus with the goal of improving outcomes. Many (neo)adjuvant trials are in phase 2/3, as seen in the breakdown below.